April 17 , 2021
1244 days
869
- An additional government funding has been received by India’s mRNA-based Covid-19 vaccine candidate-HGCO19 for its clinical studies.
- This funding has been awarded under the ‘Mission Covid Suraksha’.
- It has been developed by Pune-based biotechnology company Gennova Biopharmaceuticals in collaboration with HDT Biotech Corporation, USA.
![](https://www.tnpscthervupettagam.com/assets/home/media/general/original_image/17-118.jpg)
Post Views:
869